The Institute of Cancer Research, London, is one of the world’s most influential cancer research institutes, with an outstanding record of achievement dating back more than 100 years.
Read our new analysis – From Patent to Patient: our report analysing access to innovative cancer drugs
At the ICR we are researching how to treat the differences between cancers – an approach known as personalised medicine.
The ICR is a college of the University of London, and educating and training the next generation of cancer researchers and clinicians is a core part of our mission.
Our donors and supporters play a vital role in helping researchers at the ICR to make the discoveries that defeat cancer.
The Enterprise Unit has many industrial partners and works with them to transform ideas into new products for the benefit of cancer patients.
The ICR is led by Chief Executive, Professor Paul Workman — an expert in cancer drug discovery.
We are world leaders in identifying cancer genes, discovering cancer drugs and developing precision radiotherapy.
Together with our hospital partner The Royal Marsden NHS Foundation Trust, we are rated in the top four centres for cancer research and treatment worldwide.
As well as being as world-class research institute, the ICR is a higher education institution and a college of the University of London. We came top in the league table of university research quality compiled from the Research Excellence Framework (REF 2014).
The ICR has charitable status and relies on support from partner organisations, charities, donors and the general public.
Here in London, our scientists conduct world-leading research every day. Our mission? To defeat cancer.
For more than 100 years, the ICR has been pioneering discoveries into cancer and its treatment.
The Annual Report and Accounts provides the ICR's accounts for the end of each financial year.
The ICR has outlined its position on a number of policy issues in scientific and medical research.
We always want to hear from people who have a cancer story to share.
Get in touch and help raise awareness of our research.
Contact us to find out more about the ICR.
Our report asks how we can best harness advances in science to bring innovative drugs to patients. It is designed to help us reshape the landscape for drug discovery and development – and create tomorrow’s cancer treatments.
Our latest research shows that within the next decade, we can make acute lymphoblastic leukaemia preventable. Your support will help us make this disease a thing of the past.
The 100,000 Genomes Project has finished: what were the challenges and what comes next?
Why regulators must move with the science if we’re to get innovative new treatments to patients more quickly
The future of CAR T cell immunotherapy in the UK